Vis børsmeldingen
DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER
OF ANY OF THE SECURITIES DESCRIBED HEREIN
Reference is made to the stock exchange announcement by Aqua Bio Technology
ASA (“ABTEC” or the “Company”) on 11 March 2026 regarding the terms of a
subsequent offering of up to 800,000 new shares (the “Offer Shares”), each at
a subscription price of NOK 5.00 (the “Subsequent Offering”), and the stock
exchange announcement on 12 March 2026 regarding the start of the subscription
period in the Subsequent Offering, as well as to the preliminary results of
the Subsequent Offering announced on 20 March 2026.
The subscription period in the Subsequent Offering expired on 19 March 2026 at
16.30 CET. The Company has been informed by our settlement manager that at the
end of the Subscription Period, the Company had received valid subscriptions
for 388,240 Offer Shares in the Subsequent Offering. The board of directors
(the “Board”) has today resolved that a total of 388,240 Offer Shares will be
allocated at the Offer Price in accordance with the allocation criteria set
out in offering materials. The Board has allocated 348,240 Offer Shares to
Eligible Shareholders and 40,000 Offer Shares to Secondary Subscribers,
raising gross proceeds of NOK 1,941,200.
In connection with such allocation, the Board has also resolved to increase
the share capital of the Company with NOK 1,941,200 through the issuance of
388,240 Offer Shares, each with a par value of NOK 5.00.
Notifications of allocated Offer Shares in the Subsequent Offering and the
corresponding amount to be paid by each subscriber will be sent out in a
separate letter to each subscriber. Investors that are allocated Offer Shares
can also access information on the number of Offer Shares allocated through
the VPS. The due date for payment of the Offer Shares is on 25 March 2026.
Subject to duly and timely payment of the Offer Shares by the subscribers, the
Offer Shares are expected to be delivered to the VPS accounts of the
subscribers on or about 8 April 2026. The Offer Shares will be delivered as
listed and tradable shares. The Offer Shares will have equal rights and rank
pari passu with the Company’s other shares.
For additional information on the Subsequent Offering, including its terms and
conditions, please refer to the offering materials available on the Company’s
website, www.aquabiotechnology.com.
IMPORTANT INFORMATION
This announcement is not an offer to sell or a solicitation of offers to
purchase or subscribe for shares. Copies of this announcement may not be sent
to jurisdictions, or distributed in or sent from jurisdictions, in which this
is barred or prohibited by law. The information contained herein shall not
constitute an offer to sell or the solicitation of an offer to buy, in any
jurisdiction in which such offer or solicitation would be unlawful absent
registration, or an exemption from registration or qualification under the
securities laws of any jurisdiction.
This document is not for publication or distribution in, directly or
indirectly, Australia, Canada, Japan, Hong Kong or the United States or any
other jurisdiction in which such release, publication or distribution would be
unlawful, and it does not constitute an offer or invitation to subscribe for
or purchase any securities in such countries or in any other jurisdiction. In
particular, the document and the information contained herein should not be
distributed or otherwise transmitted into the United States or to publications
with a general circulation in the United States of America.
This announcement is not an offer for sale of securities in the United States.
Securities may not be offered or sold in the United States absent registration
with the United States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended (the
“Securities Act”). The Company does not intend to register any part of the
offering in the United States or to conduct a public offering in the United
States of the shares to which this document relates. This announcement is for
information purposes only and is not to be relied upon in substitution for the
exercise of independent judgment. It is not intended as investment advice and
under no circumstances is it to be used or considered as an offer to sell, or
a solicitation of an offer to buy any securities or a recommendation to buy or
sell any securities of the Company.
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect
current expectations and assumptions as to future events and circumstances
that may not prove accurate. A number of material factors could cause actual
results and developments to differ materially from those expressed or implied
by these forward-looking statements.
The Company expressly disclaims any obligation or undertaking to update,
review or revise any statement contained in this announcement whether as a
result of new information, future developments or otherwise.
Contacts
Kristian Flaten
CEO & CFO
Aqua Bio Technology ASA
Phone: +47 9509 2322
Email: kf@aquabiotech.no
About Us
Aqua Bio Technology ASA (ABTEC) is a technology and distribution group in
skincare and nonfood. The group has distribution towards B2C and B2B, and
offers freight, customs, and logistics services. The group also develops
sustainable biotechnology for use in skincare products. Aqua Bio Technology is
listed on Euronext Expand Oslo.
This notice is published by Kristian Flaten on the listed date and time.
This information has been submitted pursuant to the Securities Trading Act §
5-12 and MAR. The information was submitted for publication, through the
agency of the contact persons set out above, at 2026-03-23 16:28 CET.
Kilde
